Medscape2mon
Intravenous Palivizumab and Ribavirin Combination for Respiratory Syncytial Virus Disease in High-Risk Pediatric Patients
There is no consensus concerning the most effective therapy for severe RSV infection in high-risk patients. Palivizumab is approved for prevention of RSV disease, and ribavirin is approved for ...
Medscape24d
Intravenous Palivizumab and Ribavirin Combination for Respiratory Syncytial Virus Disease in High-Risk Pediatric Patients
We identified 31 hospitalized pediatric patients who received IV PVZ for treatment of acute RSV infection at our institution from October 1,2001 to July 31,2005. Twenty male and 11 female patients ...